Thoughts
First Investment: 2014
EXIT - NYSE: DNA
The solutions to many of the hardest problems in agriculture, nutrition, pharmaceuticals, energy production, and chemical and material processing lie in synthetic biology. Ginkgo runs biological foundries where automation, machine learning, and analytics work in synchrony to help partners scale up the engineering and manufacture of novel enzymes, proteins, small molecules, and microbial strains.
News & Insights
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules